NASDAQ

Cardlytics, Inc. (CDLX)

382 Thanks from members

Cardlytics, Inc. (CDLX) displays a mixed financial narrative following its Q2 2026 results, characterized by positive adjusted EBITDA and completed strategic divestitures, balanced against revenue contractions from partner exits and weak alternative data sentiment scores.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →